Home Technology Orexigen Therapeutics Continues to Rally

Orexigen Therapeutics Continues to Rally

Caesars Entertainment Corp (NASDAQ:CZR), Orexigen Therapeutics, Inc. (NASDAQ:OREX) and Fossil Group Inc (NASDAQ:FOSL) reached midday with major gains. Taking tumbles midday are Altisource Portfolio Solutions S.A. (NASDAQ:ASPS), Cal Dive International, Inc. (OTCMKTS:CDVI) and Stemline Therapeutics Inc (NASDAQ:STML).

Caesars Surges Thanks to Credit Agreement

Caesars Entertainment Corp (NASDAQ:CZR) reached midday up +27.11% thanks to reports that it has reached an agreement with creditors regarding its debt restructuring plan. Leon Cooperman, John Paulson and George Soros have positions in the casino operator, which despite today’s gain is down -34.03% YTD.

The share price of Orexigen Therapeutics, Inc. (NASDAQ:OREX) climbed +18.95% early in the day today, putting its five-day gain at +48.15%. The drug developer has gained 74.36% over the past month – much to the benefit of Farallon Capital, which as of Q2 holds 2.68 million OREX shares.


Fossil Group Inc (NASDAQ:FOSL) got an +8.16% boost this morning after surpassing analysts’ estimates on earnings and announcing a renewed deal with Michael Kors (NYSE:KORS). The company, a Ray Dalio holding, has gained +9.66% over the last three months.

Altisource Portfolio Solutions Plunges

Altisource Portfolio Solutions S.A. (NASDAQ:ASPS) plunged -21.8% today, hitting a new low after announcing that it is discontinuing its Lender Placed Insurance brokerage line of business. ASPS, a long-time Leon Cooperman holding, has declined -63.4% year-to-date.

Cal Dive International, Inc. (OTCMKTS:CDVI) continues its freefall, its price dipping -21.74% by midday today. The company was delisted from the New York Stock Exchange just last week – a tough break for billionaire investor George Soros.

Also having a rough go this Wednesday is Stemline Therapeutics Inc (NASDAQ:STML), the share price of which fell -7.56% despite beating expectations on earnings. STML, a Farallon Capital holding, is down -28.47% YTD.

Sign Up For Our Free Newsletter



A Premium Investing Resource
An Absurdly Low Price

“ValueWalk provides an invaluable service—bringing together the best and most important commentary in the world of value investing, all in one place.”

Maybe THAT kind of insight makes it clear that ValueWalk Premium is worth another look.

It seems like a pretty easy decision.

One that will help make bigger, better decisions in the future.

Exit mobile version